Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - November 2025

Cencora executive Heather Zenk discusses how innovations in cold chain, data visibility, and sustainability strategies are transforming the drug delivery process.

Building Resilient, Sustainable Pharma Supply Chains

From patent cliffs and government price controls, to self-pay models and staff-model HMOs, a look at the forces that could deflate the bubble—and those factors likely to keep it afloat a while longer.

Popping the Gross-to-Net Bubble, Part VI: The Future of Pharmaceutical Pricing

Advice for pharma distributors and dispensers on what they should do now in order to solidify a secure supply chain.

DSCSA Compliance: Milestones, More Deadlines—and the Road Ahead

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

A panel examines the gross-to-net bubble across various product mixes, how pricing impacts market access, and more.  

Trade & Channel Strategies 2024: A GTN Bubble Balancing Act

Videos

Kevin O’Meara discusses how patient service teams influence adherence from Direct-to-Patient models. 

Trade & Channel Strategies 2024: The Role of Patient Service Teams in Driving Direct-to-Patient Adherence

The latest news for pharma industry insiders.

Pharma Pulse 12/16/24: Dark Chocolate Lowers T2D Risk, Technology Accessibility & more

In the fourth part of this roundtable discussion, key opinion leaders discuss how successful RFID use cases in the food sector can translate well to pharma, including what needs to be implemented in order to see success. 

Peer Exchange: Learning from Other Industries (Episode 4)

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses the breakout session at Trade & Channel Strategies in Philadelphia.

Trade & Channel Strategies 2024: Industry Audit—Analyzing Top Biopharmaceuticals Performance Metrics

A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.  

Trade & Channel Strategies 2024: Lessons Learned and Considerations with Humira

Kevin O’Meara discusses Patient-Cetric 3.0 breakout session and the challenges of drug manufactures implementing Direct-to-Patient models.

Trade & Channel Strategies 2024: Key Challenges of Implementing Direct-to-Patient Models 

A session investigates the drivers of these shortages and ways to mitigate them. 

Trade & Channel Strategies 2024: A Deep Dive into Drug Shortages

Pharma Pulse 12/12/24: AI Skepticism to Adoption in Pharma Marketing, Biologic Treatments Transforming Severe Asthma Management & more

Breakout session explores how direct-to-patient models shorten the time to diagnosis and therapy to improve patient outcomes.

Featured Content

Pharmaceutical Commerce - November 2025

Building Resilient, Sustainable Pharma Supply Chains

Popping the Gross-to-Net Bubble, Part VI: The Future of Pharmaceutical Pricing

DSCSA Compliance: Milestones, More Deadlines—and the Road Ahead